Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors

NCT03381014 | Unknown

• 1 other identifier: speckle echo in cardiomyopathy
• Study Type: observational
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

Early detection of cardiomyopathy in patients receiving Anthracycline chemotherapy and determine if speckle tracking echo and Troponin gene will add benefit for early detection of cardiomyopathy. Improve economic impact of oncologic patients from whom high sensitive troponin negative and normal speckle tracking patients can be safely excluded from long-term cardiac monitoring programs. To correlate between the molecular gene expression of troponin genes and ryanodine receptor in cardiomyopathy

Conditions

Chemotherapy Effect

Outcome Measures

Primary Outcomes (2)

• early detection of cardiomyopathy

  using speckle tracking echo to early diagnosis of cardiomyopathy

  about one year

• identify patients whose at risk to develop cardiomyopathy

  Using the high sensitive troponin with quantitative measurements as biomarker.

  about one year

Secondary Outcomes (1)

• molecular gene expression of troponin genes and ryanodine receptor in cardiomyopathy

  same time frame ... about one year

Interventions

Chemotherapy, Cancer, Anthracyclines DRUG

follow up cardio-toxicity .... by speckle tracking echo and cardiac troponin

Also known as: speckle tracking Echo

Eligibility Criteria

• Age: 30 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Cancer patient between the age of 30-50yr who will receive chemotherapy

You may qualify if:

• all Newly diagnosed cancer patients with who will receive Anthracycline based regimen chemotherapy

You may not qualify if:

• Insufficient ultrasound image quality, defined as more than three LV segments being suboptimally visualized by conventional echocardiography.
• Valvular heart disease
• Hypertensive heart disease
• Cardiomyopathy
• Chronic renal failure
• Chronic obstructive air way disease (COPD)

Sponsors & Collaborators

• Assiut University: lead

Related Publications (2)

• Henning RJ, Harbison RD. Cardio-oncology: cardiovascular complications of cancer therapy. Future Cardiol. 2017 Jul;13(4):379-396. doi: 10.2217/fca-2016-0081. Epub 2017 Jun 29.

  PMID: 28660778 RESULT

• Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, Cipolla CM. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin. 2016 Jul;66(4):309-25. doi: 10.3322/caac.21341. Epub 2016 Feb 26.

  PMID: 26919165 RESULT

Related Links

• Cancer Chemotherapy and Cardiac Arrhythmias: A Review

MeSH Terms

Interventions

Anthracyclines

Intervention Hierarchy (Ancestors)

Naphthacenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Polycyclic Compounds; Aminoglycosides; Glycosides; Carbohydrates

Study Officials

• yehia T kishk, MD

  cardiology department

  STUDY CHAIR

• Mohamed K Koriem, MD

  cardiology department

  PRINCIPAL INVESTIGATOR

• Naglaa K Idriss, MD

  biochemistry department

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Mostafa M Morsy, MD

CONTACT

+201096955959; Mostafa_corono@yahoo.com

Hatem A helmy, MD

CONTACT

+201005212162; hatem19652007@yahoo.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: doctor

Study Record Dates

• First Submitted: December 12, 2017
• First Posted: December 21, 2017
• Study Start: January 1, 2018
• Primary Completion: January 1, 2019
• Study Completion: August 1, 2019
• Last Updated: December 21, 2017

Record last verified: 2017-12